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A ‘deeply flawed’ metanalysis of the 
life-saving interim blood alternative, 
Hemopure, published in an American 
scientific journal this April1 has led 
to at least one province and hospitals 
elsewhere avoiding its use – to their 
detriment.
Hemopure is purified haemoglobin 
in a sterile solution that acts as an 
oxygen bridge when compatible red 
blood cells are not readily available. 
It has been shown to save the lives of 
42% of haemorrhaging and severely 
anaemic patients who would otherwise 
have died, and has no lasting side-
effects.2 The product is stable at room 
temperature, has a shelf life of 3 years 
and requires no blood cross-matching.  
It is approved for ‘compassionate 
use’ in the USA, and licensed for acute 
anaemia and delaying the need for 
predictable blood transfusion (in adult 
surgical patients) in South Africa. South 
Africa is the world’s leader in all-cause 
trauma mortality, making the product 
highly relevant locally.
Izindaba spoke to the man who 
conducted the seminal research, 
University of Maryland Professor Colin 
Mackenzie, when he was in Cape Town 
this August to attend the Combined 
Congress of the Critical Care Society of 
South Africa.
Mackenzie and the manager of 
Hemopure in South Africa, Dr Mandisa 
Maholwana, revealed that since the 
controversial metanalysis appeared 
in the Journal of the American Medical 
Association (JAMA),1 in April, usage 
reticence had crept in. Maholwana said 
the KwaZulu-Natal health authorities 
had ordered doctors to stop using 
Hemopure while in Gauteng: ‘We 
recently had a case where the clinicians 
weren’t allowed to use it, so they 
sourced it from a private hospital’.
Thumbs up from Jehovah’s 
Witnesses
Both Hemopure (created using 
haemoglobin polymer synthesised 
from bovine haemoglobin) and another 
similar product, Polyheme (derived 
from human haemoglobin), are 
unconditionally accepted by Jehovah’s 
Witnesses. Members of this church have 
long prompted ethical controversy by 
refusing potentially life-saving blood 
transfusions.
Dr Anthony Reed, the provincial 
co-ordinating clinician for anaesthetic 
services in the Western Cape, said 
he encountered about ‘one Jehovah’s 
Witness patient every six months’ in 
clinical practice. Reed spoke favourably 
of Hemopure’s applications.
Maholwana said they were 
beginning to see the pharmaceutical 
and therapeutic committees (PTCs) 
of individual hospitals rejecting 
Hemopure, although luckily this 
unfounded reticence had yet to 
filter through to the national health 
department.
METANALYSIS CRITICAL OF BLOOD ALTERNATIVE 
PRODUCT CHALLENGED
‘We’re really worried 
about the rural areas, 
where urgently obtaining 
the correct type of blood 
is often so difficult or 
sometimes even impossible,’ 
she observed.
Hemopure researcher, the University of Maryland’s Professor Colin Mackenzie, and the manager of 
Hemopure in South Africa, Dr Mandisa Maholwana.
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‘We’re really worried about the rural 
areas, where urgently obtaining the 
correct type of blood is often so difficult 
or sometimes even impossible,’ she 
observed. The longest recorded period 
a patient has been kept alive (and 
survived) in South Africa on Hemopure 
is 19 hours. In the USA a patient with 
autoimmune haemolytic anaemia and a 
red cell haemoglobin 0.8 g/dl was kept 
alive for 19 days, further attesting to the 
safety of the drug. Published research 
shows that 96.3% of patients can avoid 
blood transfusion for 24 hours by using 
Hemopure.2 Mackenzie emphasised that 
correct use and repeat dosages were 
critical for optimal outcomes.
He said the metanalysis1 of 
haemoglobin-based oxygen carriers 
combined 5 different products and 
pooled 22 Hemopure studies using 
different methodologies and different 
settings on heterogeneous patient 
populations with differing controls.  It 
incorrectly concluded that there was an 
increase in mortality and myocardial 
infarction for all these products, which 
is not the case with Hemopure.
‘You can’t do a metanalysis like that. 
They pooled high mortality and low 
mortality trials. If, as the metanalysis 
suggested, all  these products were the 
same, then they should have examined 
dose response effects, but this was not 
done because of major heterogeneities 
among the trials,’ he added.
Mackenzie said he had just returned 
from a major hospital in Bloemfontein 
where clinicians spoke of losing 
three patients postpartum due to 
haemorrhage, with no available blood 
in just the past 2 months. ‘So you can 
imagine the cost in live births of not 
using Hemopure,’ he added.
Mackenzie is also the co-author of 
the largest single published study on 
the use of haemoglobin-based oxygen 
carriers in comparison to packed red 
cells for elective surgery (680 patients), 
published in June of this year in the 
Journal of Trauma, Injury, Infection and 
Critical Care. Mortality for moderate use 
(3 units of packed red blood cells or 10 
units of Hemopure) was found to be 
1% in both cohorts, and serious adverse 
events were 0.14 per patient.
Highly effective interim measure
This study found that Hemopure 
eliminated transfusion in the majority 
of subjects and that patients under 
80 years old with moderate clinical 
needs could safely avoid transfusion 
when treated with up to 10 units of 
Hemopure.3
Mackenzie said their best counter 
to what he terms ‘political issues that 
have been raised that have nothing to 
do with science’ was the inexorable 
publication of peer-reviewed gold 
standard research. He revealed that the 
US military was very keen to support 
his team’s application to use Hemopure 
in a resuscitation study of combat 
casualties in Iraq (alternative oxygen 
carriers have their research origins in 
the US military in the 1950s).
‘The money was all there, but the 
Food & Drug Administration (FDA) 
had safety concerns related to what they 
called hypertension’ (what Mackenzie 
prefers to call ‘transient elevation of 
blood pressure’). 
In a public FDA hearing, the voting 
revealed a dramatic split – all the 
clinicians voted in favour and all the 
‘blood bankers and non-clinicians’ 
voted against. Mackenzie said the 
elevation of systolic blood pressure of 
23 mm of mercury on the first infusion 
of Hemopure and 10 mm on subsequent 
infusions was ‘clinically irrelevant’.
‘The blood bank people think it’s 
dangerous, yet nobody’s ever done 
a clinical trial of blood!  Hemopure 
simply fills the gap until blood becomes 
available,’ he stressed.
Prompted to share the costs of 
Hemopure, Maholwana revealed that 
the single exit price was R3 500 per unit 
(VAT incl.) in the public sector and R5 
800 (VAT incl.) in the private sector.
Pricing comparisons ‘impossible’
Maholwana said it was ‘virtually 
impossible’ to establish the comparative 
cost of blood as the hidden costs of 
transfusion, collection, cross-matching, 
screening, storage, delivery and 
restocking every 6 weeks remained 
hidden, especially in the public sector. 
‘I’ve been to two different hospitals and 
got two entirely different unit prices 
– they pay the blood bank and the lab…
they just don’t know,’ she said.
Mackenzie said what the publication 
of the metanalysis in the JAMA had 
done was ‘polarise people into believing 
that all haemoglobin oxygen carriers 
are the same, which they are not’. 
Given the critical blood shortage in 
many countries, especially around 
festive seasons, ‘it’s important that we 
remember that if you don’t have blood, 
there’s nothing else. People should open 
up their minds,’ he added.
In the USA the projected shortfall of 
blood by the year 2014 was 4 million 
units, a potent illustration of just how 
important this product application may 
become.4
Chris Bateman
1.    Natanson C, Wolfe S. JAMA 2008; 299: 2324-2326.
2.    Moon-Massat PF, Mackenzie C, Shander A, Greenburg AG. 
Paper presented at the Critical Care and Thoracic Society 
Conference, Cape Town, August 2008.
3.    Journal of Trauma, Injury, Infection and Critical Care 2008; 64 
(6): 1484-1497.
4.    Vamvakas EC. Epidemiology of red cell utilization. 
Transfus Med Rev 1996; 19: 44-61.
October 2008, Vol. 98, No. 10  SAMJ
MOME000182_HelpHand_297x210 8/22/08 3:17 PM Page 1 
Composite
pg740-752.indd   748 9/29/08   12:05:24 PM
IZINDABA
752
retirement savings for life crises when 
they leave their employer.
‘South Africans often withdraw their 
savings before retirement to educate 
their kids, provide income in times 
of illness and death or buy a small 
business. Fear of not having access 
to these savings in future is currently 
worsening the outflow,’ she explains.
This is aggravated by HIV and AIDS 
and the accompanying stigma, fuelling 
unemployment and draining 34% of 
household expenditure in affected 
families. While Metropolitan was ‘very 
sensitive’ to the interests of low-income 
earners who need access to savings 
for life crises, it had to emphasise the 
crucial importance of preserving funds, 
she said.
Retirement funds used for 
emergencies
Many middle- and higher-income 
classes in South Africa also withdrew 
from their retirement savings during 
their working lives, leading to 
inadequate financial protection in 
retirement. It was ‘common knowledge’ 
in the insurance industry that if you 
cashed in the retirement savings of the 
first 10 years of your career, it would 
reduce your pension by around 40%.
‘We want to reduce people’s 
dependency on government when 
they retire by forcing them to save 
throughout their lifetime. Yet if they 
do that and end up not having enough 
money to look after the sick and jobless 
on their way there, it will increase the 
social burden on the state.’
Fortunately, government recognised 
this and spoke in its discussion papers 
of the urgent need to broaden social 
security while encouraging job creation 
and protecting disposable income. 
When it came to HIV and AIDS, it 
was far cheaper to treat someone with 
antiretroviral therapy (ART) than to pay 
out a death benefit (typically 3 times 
one’s annual salary). Nicolay compared 
the R6 000 cost of a year’s ART versus 
paying out, for example, R45 000 in 
death benefits for a person earning 
R15 000 a year. Added to this were the 
medical costs of treating opportunistic 
infections, lower productivity and 
higher unemployment.
Upscaling prevention and 
treatment vital
 ‘It has to be cost effective to invest 
heavily in prevention and treatment 
of employed people instead of giving 
them a fund that will pay out millions 
in death and disability benefits. The 
NSSF will then be able to focus more on 
saving and preservation for old age, as 
was the original intention,’ she adds.
Nicolay hit headlines 2 years ago 
when she outlined her ‘four seasons’ 
2025 AIDS scenarios with the ‘Winter 
of discontent’, featuring weak self-
serving leadership, high crime and an 
AIDS response involving fake cures and 
corrupt systems. 
She predicted continuous deaths in 
the workplace leading to companies 
closing down, with only 1 in 5 South 
Africans knowing their status by 2010 
and the life expectancy remaining at 
50 years. In stark contrast, the 2025 
‘Summer for all people’ featured strong 
collaborative leadership committed 
to a developmental society, led by 
government, a focus on prevention with 
treatment, and care. Proactive business 
would be sustainable as the epidemic 
shrank, with up to 60% of people 
knowing their status by 2010 and only 
7% of the employed population being 
infected by 2025. 
An estimated 20% of all South 
Africans between the ages of 20 and 64 
are currently HIV positive.
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Nicolay compared the 
R6 000 cost of a year’s 
ART versus paying out, 
for example, R45 000 in 
death benefits for a person 
earning R15 000 a year.
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